DK3921033T3 - Arginasehæmmere og fremgangsmåder til anvendelse deraf - Google Patents

Arginasehæmmere og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3921033T3
DK3921033T3 DK20709706.4T DK20709706T DK3921033T3 DK 3921033 T3 DK3921033 T3 DK 3921033T3 DK 20709706 T DK20709706 T DK 20709706T DK 3921033 T3 DK3921033 T3 DK 3921033T3
Authority
DK
Denmark
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
DK20709706.4T
Other languages
Danish (da)
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3921033T3 publication Critical patent/DK3921033T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK20709706.4T 2019-02-08 2020-02-07 Arginasehæmmere og fremgangsmåder til anvendelse deraf DK3921033T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3921033T3 true DK3921033T3 (da) 2023-10-16

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20709706.4T DK3921033T3 (da) 2019-02-08 2020-02-07 Arginasehæmmere og fremgangsmåder til anvendelse deraf

Country Status (32)

Country Link
US (2) US12435097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759971B1 (cg-RX-API-DMAC7.html)
CN (1) CN113395996B (cg-RX-API-DMAC7.html)
AU (1) AU2020218651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015581A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011039A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210463A (cg-RX-API-DMAC7.html)
DK (1) DK3921033T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2021000166A (cg-RX-API-DMAC7.html)
EA (1) EA202192114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960034T3 (cg-RX-API-DMAC7.html)
FI (1) FI3921033T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231092T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062968T2 (cg-RX-API-DMAC7.html)
IL (1) IL285108B2 (cg-RX-API-DMAC7.html)
LT (1) LT3921033T (cg-RX-API-DMAC7.html)
MA (1) MA56324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009499A (cg-RX-API-DMAC7.html)
MY (1) MY206577A (cg-RX-API-DMAC7.html)
PE (1) PE20220280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551902A1 (cg-RX-API-DMAC7.html)
PL (1) PL3921033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3921033T (cg-RX-API-DMAC7.html)
RS (1) RS64781B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108503PA (cg-RX-API-DMAC7.html)
SI (1) SI3921033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300337T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020161675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) * 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
AU2020218651B2 (en) 2023-01-12
MY206577A (en) 2024-12-24
JP2022521474A (ja) 2022-04-08
KR102759971B1 (ko) 2025-01-23
DOP2021000166A (es) 2021-09-30
HRP20231092T1 (hr) 2023-12-22
IL285108B1 (en) 2024-06-01
IL285108A (en) 2021-09-30
MX2021009499A (es) 2021-09-08
KR20210126044A (ko) 2021-10-19
PL3921033T3 (pl) 2024-01-15
BR112021015581A2 (pt) 2021-10-05
HUE062968T2 (hu) 2023-12-28
CL2021002056A1 (es) 2022-03-04
ZA202105833B (en) 2025-03-26
ES2960034T3 (es) 2024-02-29
PE20220280A1 (es) 2022-02-25
CR20210463A (es) 2021-10-15
IL285108B2 (en) 2024-10-01
WO2020161675A1 (en) 2020-08-13
CN113395996A (zh) 2021-09-14
US20220106335A1 (en) 2022-04-07
RS64781B1 (sr) 2023-11-30
EA202192114A1 (ru) 2021-12-01
SG11202108503PA (en) 2021-09-29
EP3921033B1 (en) 2023-07-26
JP7526734B2 (ja) 2024-08-01
US12435097B2 (en) 2025-10-07
CA3127755A1 (en) 2020-08-13
PH12021551902A1 (en) 2022-08-01
SMT202300337T1 (it) 2023-11-13
FI3921033T3 (fi) 2023-09-15
CN113395996B (zh) 2024-05-28
EP3921033A1 (en) 2021-12-15
SI3921033T1 (sl) 2023-11-30
LT3921033T (lt) 2023-09-25
CO2021011039A2 (es) 2021-09-09
AU2020218651A1 (en) 2021-09-30
US20250282800A1 (en) 2025-09-11
MA56324B1 (fr) 2023-10-31
DOP2024000181A (es) 2024-10-15
PT3921033T (pt) 2023-10-11

Similar Documents

Publication Publication Date Title
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
DK3752251T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3840837T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK4084778T3 (da) Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
DK3852533T3 (da) Pyridazinoner og fremgangsmåder til anvendelse deraf
DK3788045T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
DK4200018T3 (da) Anti-par-2-antistoffer og fremgangsmåder til anvendelse deraf
DK3793995T3 (da) Matrix metalloproteinase (MMP)-inhibitorer og fremgangsmåder til anvendelse deraf
IL292860A (en) Allosteric egfr inhibitors and methods of use thereof
ZA202105833B (en) Arginase inhibitors and methods of use thereof
DK3930838T3 (da) N-(pyridinyl)acetamidderivater som p300/cbp-hat-hæmmere og fremgangsmåder til anvendelse deraf
IL309389A (en) E3 ligase inhibitors and methods of use thereof